Arix Bioscience plc notes positive trial data from Verona Pharma in COPD
07 September 2017 - 11:06PM
Arix Bioscience plc notes positive trial data
from Verona Pharma in COPD
LONDON, 7 September 2017: Arix Bioscience
plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life
science company supporting medical innovation, is pleased to note
the announcement by Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA)
("Verona Pharma"), an Arix Bioscience Group Business, of positive
top-line results from its Phase 2a clinical trial for RPL554 in
patients with moderate-to-severe chronic obstructive pulmonary
disease (COPD).
The data from this Phase 2a trial demonstrated
statistically significant and clinically meaningful improvement in
peak lung function and a faster onset of action when Verona
Pharma's RPL554 was added to tiotropium (Spiriva®), one of the most
commonly used drugs to treat COPD, versus tiotropium alone.
The double-blind, placebo-controlled, three way
cross-over trial in 30 subjects with moderate-to-severe COPD
demonstrated statistical significance across all primary and
secondary efficacy outcome measures at the 6mg dose, a clear dose
response compared to the 1.5mg dose, and both doses of RPL554 were
well tolerated.
RPL554 is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have
anti-inflammatory as well as bronchodilator properties, and is
currently in development for the maintenance treatment of COPD
patients and for the treatment of patients with cystic
fibrosis.
Verona Pharma continues to enroll patients in
its Phase 2b study to assess nebulised RPL554 for the maintenance
treatment of COPD.
Joe Anderson, Chief Executive Officer of Arix
Bioscience, commented: "We are very pleased to note Verona
Pharma's positive trial data, which clearly demonstrates the
clinical benefit of its product as an add-on treatment to one of
the most widely prescribed drugs for COPD. Verona Pharma is a
dynamic company with an important drug asset, and today's data
further reinforces our belief in its potential to address
significant unmet needs in respiratory medicine."
For more information, please contact:
Arix Bioscience plcJoe Anderson, CEO+44
(0) 20 7290 1052
Matthew Cole, Communications Director+44 (0) 20
7290 1065
Consilium Strategic
CommunicationsMary-Jane Elliott, Jessica Hodgson, Ivar
Milligan+44 (0)20 3709 5700arix@consilium-comms.com
About Arix Bioscience plcArix Bioscience
plc is a global healthcare and life science company supporting
medical innovation. Headquartered in London and with an
office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market
of the London Stock Exchange.
For further information, please
visit www.arixbioscience.com
About Verona Pharma plc Verona Pharma is
a clinical-stage biopharmaceutical company focused on developing
and commercialising innovative therapeutics for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled,
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts
as both a bronchodilator and an anti-inflammatory agent in a single
compound. In clinical trials, treatment with RPL554 has been
observed to result in statistically significant improvements in
lung function as compared to placebo and has shown clinically
meaningful and statistically significant improvements in lung
function when added to two commonly used bronchodilators as
compared to either bronchodilator administered as a single agent.
Verona Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD), cystic fibrosis, and
potentially asthma.
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024